Current Opinion in HIV and AIDS

Neutralizing antibodies for HIV-1 prevention.

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV

Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis

Long-acting injectable cabotegravir for the prevention of HIV infection.

Current and future priorities for the development of optimal HIV drugs

Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection

The arc of HIV epidemics in sub-Saharan Africa: new challenges with concentrating epidemics in the era of 90-90-90.

Broadly neutralizing antibodies for the treatment and prevention of HIV infection.

Comparative analysis of HIV sequences in real time for public health

Polypharmacy in HIV: recent insights and future directions.

Long-acting implants to treat and prevent HIV infection.

B-cell abnormalities in HIV-1 infection: roles for IgG3 and T-bet.

Understanding disclosed and cryptic HIV transmission risk via genetic analysis: what are we missing and when does it matter?

Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1.

Reaching 90-90-90 in rural communities in East Africa: lessons from the Sustainable East Africa Research in Community Health Trial.

Challenges of reaching 90-90-90 in the Southern United States.

HIV-1 antibodies in prevention of transmission.

New Th17-specific therapeutic strategies for HIV remission

Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure

Human cytomegalovirus-vectored vaccines against HIV

The first 90: the gateway to prevention and care: opening slowly, but not for all.

HIV-1 reservoir dynamics in CD4+ T cells

Follicular T-cell subsets in HIV infection: recent advances in pathogenesis research

What lessons it might teach us? Community engagement in HIV research.

Role of cytokine agonists and immune checkpoint inhibitors toward HIV remission

Vaccinal effect of HIV-1 antibody therapy.

Diagnosing active tuberculosis in people living with HIV: an ongoing challenge

Review: HIV-1 phylogeny during suppressive antiretroviral therapy

Strategies to improve access for MSM in low-income and middle-income countries.

Prisons: ignore them at our peril.

Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection: a regulatory perspective.

Coevolution of HIV-1 and broadly neutralizing antibodies.

HIV treatment and prevention 2019: current standards of care.

The cost of reaching the 90-90-90 targets: are current investments enough?

Correlates of broadly neutralizing antibody development.

HIV/tuberculosis/hepatitis C virus services for incarcerated populations in Azerbaijan and the Eastern Europe Central Asia region

Multimorbidity patterns in people with HIV.

Behavioral and social science research to support accelerated and equitable implementation of long-acting preexposure prophylaxis.

Factors influencing HIV-1 phylogenetic clustering

Is reaching 90-90-90 enough to end AIDS? Lessons from Amsterdam.

Fast-Track Cities: striving to end urban HIV epidemics by 2030.

Mitochondria and ageing with HIV.

Reaching 90-90-90 in Botswana.

Demanding an end to tuberculosis: treatment of tuberculosis infection among persons living with and without HIV

Universal health coverage and key populations.

Demand creation for primary biomedical prevention: identifying lessons across interventions to inform daily oral preexposure prophylaxis programs

What is the collective effect of aging and HIV on the gut microbiome?